HTA is used to inform policy and decision-makers in health care, especially on how best to allocate limited funds to health interventions and technologies. In accordance with the WHO, HTA is the systematic evaluation of properties, effects and/or impacts of health technologies, including both the direct, intended consequences of technologies and their indirect, unintended consequences.
In this context, health technology is a general term for any form of health intervention, including diagnostic, monitoring and treatment methods, pharmaceuticals, medical devices, care pathways, ICT and organizational systems used in health care.
HealThink has deeply realized HTA’s value to the sustainability of the health and social security system, supporting decision-makers with systematic and unbiased assessments to receive difficult decisions. The other stakeholders are equally important for us. The producers of health technologies and the providers of health care services invest money and efforts on research and innovation and they expect the return on their investments. HealThink supports them in the critical steps of approval, pricing and reimbursement of their products. We also support our clients to develop health-economic arguments and apply market-access strategies in order to provide effective solutions and maximize revenue potential.
Our company has been acknowledged for its the unique combination of expertise in HTA, having collaborated with numerous clients and implemented various HTA strategies across Europe. Our team has supported international consortia to perform HTA for innovative and integrated care services. We are proud to have worked closely with decision-makers, pharma industry, researchers and health professionals in many European countries, offering site-tailored solutions.
Our interdisciplinary team can support you in the following fields:
Health Economics
In this context, health technology is a general term for any form of health intervention, including diagnostic, monitoring and treatment methods, pharmaceuticals, medical devices, care pathways, ICT and organizational systems used in health care.
HealThink has deeply realized HTA’s value to the sustainability of the health and social security system, supporting decision-makers with systematic and unbiased assessments to receive difficult decisions. The other stakeholders are equally important for us. The producers of health technologies and the providers of health care services invest money and efforts on research and innovation and they expect the return on their investments. HealThink supports them in the critical steps of approval, pricing and reimbursement of their products. We also support our clients to develop health-economic arguments and apply market-access strategies in order to provide effective solutions and maximize revenue potential.
Our company has been acknowledged for its the unique combination of expertise in HTA, having collaborated with numerous clients and implemented various HTA strategies across Europe. Our team has supported international consortia to perform HTA for innovative and integrated care services. We are proud to have worked closely with decision-makers, pharma industry, researchers and health professionals in many European countries, offering site-tailored solutions.
Our interdisciplinary team can support you in the following fields:
Health Economics
- Cost-of-illness analysis
- Cost-effectiveness analysis
- Cost-utility analysis
- Budget impact analysis
- Modelling and simulation
- MAST framework for eHealth/telemedicine
- MAST-IC framework for integrated care
Market Access
- Market access strategy
- Local value dossier
- Product monograph
- Evidence-based messaging
- Payer message development
- Advisory boards
- Patient education material
We can help you optimize the use of your resources, develop HTA arguments and models, plan your evidence generation, define product performance, all targeted at commercial viability and maximum performance.
Our clients:
Our clients:
- Pharmaceutical companies
- Medical Devices Manufactures
- Universities and Research Institutes
- Public organizations
- Hospitals
- eHealth/mHealth companies
- Regional Health Authorities
- Municipalities/Regions
- Consulting firms and CROs
Our achievements:
We have developed successful health economic models and innovative market access strategies for pharmaceutical companies. Our dedicated team has supported international consortia to perform HTA for updated and integrated care services. We are proud to have worked together with decision-makers, pharma industry, researchers and health professionals in many European countries, offering site-tailored solutions.
We’ll help you work out a clear pathway towards commercial success.